Summary
52 / 100 · Bulios Score
What speaks for it
None of the indicators we track stands out on the positive side.
What to watch
- Earnings per share fell by 10% a year over the last 3 years.
- Out of every 100 USD of revenue, only 1.2 USD is left as net profit.
- Repaying its net debt would take 3.8 years of operating profit.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapToday you pay 22.3 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 7.2% a year over the last 3 years. For the next fiscal year analysts expect revenue to grow by 2.2%. Earnings per share fell by 10% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 70 USD
- Sales and administration 22 USD
- Taxes and other 6.3 USD
- Net profit 1.2 USD
Net profit, industry median (Medical - Care Facilities) 6.7 USD
Out of every 100 USD of revenue, 1.2 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 7.5 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 8
- Hold 3
- Sell 1
Today's price within the analysts' price targets
The average target of $12.67 is 3.3% above today's price. 67% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Reportable Segment 100%
By region
The company reports no revenue by region.
Reportable Segment brings in 100% of revenue.
Segments in detail